S&P 500   5,125.12 (+0.57%)
DOW   39,068.10 (+0.18%)
QQQ   443.67 (+1.06%)
AAPL   177.67 (-1.70%)
MSFT   412.93 (-0.17%)
META   499.76 (+1.96%)
GOOGL   137.95 (-0.37%)
AMZN   177.93 (+0.66%)
TSLA   201.93 (+0.02%)
NVDA   817.70 (+3.36%)
NIO   5.84 (+1.57%)
AMD   200.35 (+4.06%)
BABA   74.80 (+1.04%)
T   16.99 (+0.35%)
F   12.48 (+0.32%)
MU   95.47 (+5.36%)
CGC   3.27 (-0.61%)
GE   159.23 (+1.49%)
DIS   111.79 (+0.19%)
AMC   4.46 (+3.24%)
PFE   26.61 (+0.19%)
PYPL   60.56 (+0.36%)
XOM   106.10 (+1.51%)
S&P 500   5,125.12 (+0.57%)
DOW   39,068.10 (+0.18%)
QQQ   443.67 (+1.06%)
AAPL   177.67 (-1.70%)
MSFT   412.93 (-0.17%)
META   499.76 (+1.96%)
GOOGL   137.95 (-0.37%)
AMZN   177.93 (+0.66%)
TSLA   201.93 (+0.02%)
NVDA   817.70 (+3.36%)
NIO   5.84 (+1.57%)
AMD   200.35 (+4.06%)
BABA   74.80 (+1.04%)
T   16.99 (+0.35%)
F   12.48 (+0.32%)
MU   95.47 (+5.36%)
CGC   3.27 (-0.61%)
GE   159.23 (+1.49%)
DIS   111.79 (+0.19%)
AMC   4.46 (+3.24%)
PFE   26.61 (+0.19%)
PYPL   60.56 (+0.36%)
XOM   106.10 (+1.51%)
S&P 500   5,125.12 (+0.57%)
DOW   39,068.10 (+0.18%)
QQQ   443.67 (+1.06%)
AAPL   177.67 (-1.70%)
MSFT   412.93 (-0.17%)
META   499.76 (+1.96%)
GOOGL   137.95 (-0.37%)
AMZN   177.93 (+0.66%)
TSLA   201.93 (+0.02%)
NVDA   817.70 (+3.36%)
NIO   5.84 (+1.57%)
AMD   200.35 (+4.06%)
BABA   74.80 (+1.04%)
T   16.99 (+0.35%)
F   12.48 (+0.32%)
MU   95.47 (+5.36%)
CGC   3.27 (-0.61%)
GE   159.23 (+1.49%)
DIS   111.79 (+0.19%)
AMC   4.46 (+3.24%)
PFE   26.61 (+0.19%)
PYPL   60.56 (+0.36%)
XOM   106.10 (+1.51%)
S&P 500   5,125.12 (+0.57%)
DOW   39,068.10 (+0.18%)
QQQ   443.67 (+1.06%)
AAPL   177.67 (-1.70%)
MSFT   412.93 (-0.17%)
META   499.76 (+1.96%)
GOOGL   137.95 (-0.37%)
AMZN   177.93 (+0.66%)
TSLA   201.93 (+0.02%)
NVDA   817.70 (+3.36%)
NIO   5.84 (+1.57%)
AMD   200.35 (+4.06%)
BABA   74.80 (+1.04%)
T   16.99 (+0.35%)
F   12.48 (+0.32%)
MU   95.47 (+5.36%)
CGC   3.27 (-0.61%)
GE   159.23 (+1.49%)
DIS   111.79 (+0.19%)
AMC   4.46 (+3.24%)
PFE   26.61 (+0.19%)
PYPL   60.56 (+0.36%)
XOM   106.10 (+1.51%)
NASDAQ:TXG

10x Genomics (TXG) Stock Price, News & Analysis

$46.54
-0.10 (-0.21%)
(As of 12:22 PM ET)
Today's Range
$45.53
$46.86
50-Day Range
$41.56
$57.55
52-Week Range
$33.79
$63.57
Volume
308,701 shs
Average Volume
1.42 million shs
Market Capitalization
$5.55 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$62.44

10x Genomics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
34.5% Upside
$62.44 Price Target
Short Interest
Bearish
5.39% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.38mentions of 10x Genomics in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$678,786 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.48) to ($0.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.80 out of 5 stars

Medical Sector

53rd out of 957 stocks

Analytical Instruments Industry

1st out of 28 stocks


TXG stock logo

About 10x Genomics Stock (NASDAQ:TXG)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

TXG Stock Price History

TXG Stock News Headlines

Revolutionary Device Redefines Cancer Detection
Discover the breakthrough device that could transform the lives of the estimated 68 million Americans affected by skin cancer. Achieving unprecedented accuracy, this device identifies cancer's molecular signature in just 1.5 seconds. This innovation marks a rapid advance in the battle against cancer. See how investors are unlocking 10% in bonus shares for a limited time.
Revolutionary Device Redefines Cancer Detection
Discover the breakthrough device that could transform the lives of the estimated 68 million Americans affected by skin cancer. Achieving unprecedented accuracy, this device identifies cancer's molecular signature in just 1.5 seconds. This innovation marks a rapid advance in the battle against cancer. See how investors are unlocking 10% in bonus shares for a limited time.
Q4 2023 10X Genomics Inc Earnings Call
10x Genomics: Q4 Earnings Insights
10x Genomics Q4 2023 Earnings Preview
Preview: 10x Genomics's Earnings
10X Genomics Inc (TXG)
See More Headlines
Receive TXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
3/01/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:TXG
Fax
N/A
Employees
1,243
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$62.44
High Stock Price Target
$75.00
Low Stock Price Target
$54.00
Potential Upside/Downside
+33.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-255,100,000.00
Pretax Margin
-40.21%

Debt

Sales & Book Value

Annual Sales
$618.73 million
Book Value
$6.22 per share

Miscellaneous

Free Float
106,476,000
Market Cap
$5.56 billion
Optionable
Optionable
Beta
1.92
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Serge Saxonov Ph.D. (Age 47)
    Co-Founder, CEO & Director
    Comp: $837.68k
  • Dr. Benjamin J. Hindson Ph.D. (Age 49)
    Co-Founder, President, Chief Scientific Officer & Director
    Comp: $615.96k
  • Mr. Justin J. McAnearMr. Justin J. McAnear (Age 48)
    Chief Financial Officer
    Comp: $535.91k
  • Mr. Eric S. Whitaker Esq. (Age 57)
    Chief Legal Officer
    Comp: $558.97k
  • Mr. Michael Schnall-Levin
    Founding Scientist & CTO
  • Ms. Cassie Corneau
    Manager of Investor Relations and Strategic Finance
  • Ms. Rebecca Port
    Chief People Officer
  • Mr. James Bryant
    Director of Legal
  • Mr. Nikhil Rao
    Director of Product Management
  • Mr. Florian Baumgartner
    Senior Product Manager














TXG Stock Analysis - Frequently Asked Questions

Should I buy or sell 10x Genomics stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TXG shares.
View TXG analyst ratings
or view top-rated stocks.

What is 10x Genomics' stock price target for 2024?

9 brokers have issued 1 year target prices for 10x Genomics' shares. Their TXG share price targets range from $54.00 to $75.00. On average, they anticipate the company's stock price to reach $62.44 in the next twelve months. This suggests a possible upside of 34.5% from the stock's current price.
View analysts price targets for TXG
or view top-rated stocks among Wall Street analysts.

How have TXG shares performed in 2024?

10x Genomics' stock was trading at $55.96 on January 1st, 2024. Since then, TXG shares have decreased by 17.1% and is now trading at $46.41.
View the best growth stocks for 2024 here
.

When is 10x Genomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our TXG earnings forecast
.

How were 10x Genomics' earnings last quarter?

10x Genomics, Inc. (NASDAQ:TXG) posted its quarterly earnings results on Thursday, February, 15th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.05. The business had revenue of $183.98 million for the quarter, compared to analyst estimates of $182.73 million. 10x Genomics had a negative trailing twelve-month return on equity of 28.82% and a negative net margin of 41.17%. The firm's revenue was up 17.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.15) EPS.

What guidance has 10x Genomics issued on next quarter's earnings?

10x Genomics issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $670.0 million-$690.0 million, compared to the consensus revenue estimate of $702.1 million.

What is Serge Saxonov's approval rating as 10x Genomics' CEO?

25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did 10x Genomics IPO?

(TXG) raised $297 million in an IPO on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Cowen was co-manager.

Who are 10x Genomics' major shareholders?

10x Genomics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.62%), Baillie Gifford & Co. (6.70%), ARK Investment Management LLC (3.42%), Sands Capital Management LLC (3.04%), Brown Capital Management LLC (2.98%) and Price T Rowe Associates Inc. MD (2.63%). Insiders that own company stock include Benjamin J Hindson, Benjamin J Hindson, Bradford Crutchfield, James Wilbur, John R Stuelpnagel, John R Stuelpnagel, Justin J Mcanear, Justin J Mcanear, Mathai Mammen, Serge Saxonov and Sridhar Kosaraju.
View institutional ownership trends
.

How do I buy shares of 10x Genomics?

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TXG) was last updated on 3/1/2024 by MarketBeat.com Staff